DrugPatentWatch Database Preview
Drugs in Development Information for ISV-305
» See Plans and Pricing
What is the development status for investigational drug ISV-305?
ISV-305 is an investigational drug.
There have been 15 clinical trials for ISV-305.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 4th 2019.
The most common disease conditions in clinical trials are Cataract, Inflammation, and Conjunctivitis. The leading clinical trial sponsors are InSite Vision, Bausch & Lomb Incorporated, and University of California, San Diego.
There are two US patents protecting this investigational drug and forty-two international patents.
Summary for ISV-305
| US Patents | 2,415 |
| International Patents | 42,605 |
| US Patent Applications | 4,372 |
| WIPO Patent Applications | 2,803 |
| Japanese Patent Applications | 204 |
| Clinical Trial Progress | Phase 3 (2019-12-04) |
| Vendors | 71 |
Recent Clinical Trials for ISV-305
| Title | Sponsor | Phase |
|---|---|---|
| Rib Fracture Analgesia Using Cryoanalgesia | Epimed International | Phase 4 |
| Rib Fracture Analgesia Using Cryoanalgesia | University of Florida | Phase 4 |
| Rib Fracture Analgesia Using Cryoanalgesia | University of California, San Diego | Phase 4 |
Clinical Trial Summary for ISV-305
Top disease conditions for ISV-305
Top clinical trial sponsors for ISV-305
US Patents for ISV-305
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ISV-305 | Start Trial | Methods and compositions for producing hepatocyte-like cells | The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) | Start Trial |
| ISV-305 | Start Trial | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | Janssen Pharmaceutica NV (Beerse, BE) | Start Trial |
| ISV-305 | Start Trial | Pharmaceutical compounds | Cascadian Therapeutics, Inc. (Seattle, WA) | Start Trial |
| ISV-305 | Start Trial | Fused pyrimidines as inhibitors of P97 complex | Cleave Biosciences, Inc. (Burlingame, CA) | Start Trial |
| ISV-305 | Start Trial | Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma | Massachusetts Eye and Ear Infirmary (Boston, MA) | Start Trial |
| ISV-305 | Start Trial | Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D- ]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate | Millennium Pharmacetuicals, Inc. (Cambridge, MA) | Start Trial |
| ISV-305 | Start Trial | Cured gel and method of making | ATRIUM MEDICAL CORPORATION (Merrimack, NH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ISV-305
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ISV-305 | Canada | CA2959117 | 2033-09-19 | Start Trial |
| ISV-305 | Denmark | DK3046628 | 2033-09-19 | Start Trial |
| ISV-305 | European Patent Office | EP3046628 | 2033-09-19 | Start Trial |
| ISV-305 | European Patent Office | EP3685884 | 2033-09-19 | Start Trial |
| ISV-305 | Spain | ES2767062 | 2033-09-19 | Start Trial |
| ISV-305 | Japan | JP2016529920 | 2033-09-19 | Start Trial |
| ISV-305 | Japan | JP2020114237 | 2033-09-19 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
